American Association for Cancer Research
00085472can161019-sup-164878_2_supp_3582139_yy9jyv.pptx (1.41 MB)

supplemental figure 4 from Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells

Download (1.41 MB)
posted on 2023-03-31, 00:00 authored by Yijiang Shi, Tracy R. Daniels-Wells, Patrick Frost, Jihye Lee, Richard S. Finn, Carolyne Bardeleben, Manuel L. Penichet, Michael E. Jung, Joseph Gera, Alan Lichtenstein

SUPPL FIG 4: A) 8226 cells treated +/- NSC 126405 for 18 hrs followed by immunoblot assays. Fold BIM increase is determined by densitometry, mean of 3 experiments; B) Control (shSCR) or RAPTOR-silenced 8226 cells (shRAPTOR) treated +/- NSC 126405 for 18 hrs followed by immunoblot assays. Fold BIM increase is mean of 3 experiments.



UCLA AIDS Institute



DEPTOR is a 48 kDa protein that binds to mTOR and inhibits this kinase in TORC1 and TORC2 complexes. Overexpression of DEPTOR specifically occurs in a model of multiple myeloma. Its silencing in multiple myeloma cells is sufficient to induce cytotoxicity, suggesting that DEPTOR is a potential therapeutic target. mTORC1 paralysis protects multiple myeloma cells against DEPTOR silencing, implicating mTORC1 in the critical role of DEPTOR in multiple myeloma cell viability. Building on this foundation, we interrogated a small-molecule library for compounds that prevent DEPTOR binding to mTOR in a yeast-two-hybrid assay. One compound was identified that also prevented DEPTOR–mTOR binding in human myeloma cells, with subsequent activation of mTORC1 and mTORC2. In a surface plasmon resonance (SPR) assay, the compound bound to recombinant DEPTOR but not to mTOR. The drug also prevented binding of recombinant DEPTOR to mTOR in the SPR assay. Remarkably, although activating TORC1 and TORC2, the compound induced apoptosis and cell-cycle arrest in multiple myeloma cell lines and prevented outgrowth of human multiple myeloma cells in immunodeficient mice. In vitro cytotoxicity against multiple myeloma cell lines was directly correlated with DEPTOR protein expression and was mediated, in part, by the activation of TORC1 and induction of p21 expression. Additional cytotoxicity was seen against primary multiple myeloma cells, whereas normal hematopoietic colony formation was unaffected. These results further support DEPTOR as a viable therapeutic target in multiple myeloma and suggest an effective strategy of preventing binding of DEPTOR to mTOR. Cancer Res; 76(19); 5822–31. ©2016 AACR.

Usage metrics

    Cancer Research



    Ref. manager